2026 ICD-10-CM Diagnosis Code QA0.0159Neurodevelopmental disorder, related to other genes associated with transcription and gene expression
QA0.0159 is a billable ICD-10-CM diagnosis code for neurodevelopmental disorder, related to other genes associated with transcription and gene expression. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 564 through 566. The code is exempt from POA reporting.
Code Identity
Code Classification
Present on Admission (POA)Billing
QA0.0159 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Disorder (of) - See Also: Disease;
- other
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Disorder(of)
- neurodevelopmental
- other
- related to other genes associated with transcription and gene expression
Code History & ChangesHistory
New Code QA0.0159 was added to the ICD-10-CM code set for FY 2026, effective October 1, 2025.
Replacement QA0.0159 replaces the following previously assigned code(s):
- F89 - Unspecified disorder of psychological development
Questions About QA0.0159Overview
Is QA0.0159 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report neurodevelopmental disorder, related to other genes associated with transcription and gene expression on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does QA0.0159 group to?
When neurodevelopmental disorder, related to other genes associated with transcription and gene expression is the principal diagnosis on an inpatient stay, it groups to MS-DRG 564, 565, 566, with relative weights from 0.7493 to 1.5436 depending on complications. Higher weights mean higher Medicare reimbursement.
Is QA0.0159 exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for neurodevelopmental disorder, related to other genes associated with transcription and gene expression on inpatient claims.
